k
keynews.ai
keynews.ai
MoneyThe story, in brief

Eli Lilly signs $2bn deal for AI drug development with Hong Kong biotech

$2B. That's what Eli Lilly just committed to AI drug development—signaling where pharma sees the real ROI.

Reporting by Financial Times Technology 1 min brief
Paper-cut illustration of amber paths carrying capital toward a small coral research venture between larger buildings.
Capital and the next generation of AI ventures.AI illustration by KeyNews
The KeyNews take

Why it matters

A Fortune 500 pharmaceutical giant betting $2B on AI-driven drug discovery with a Hong Kong biotech partner signals mainstream enterprise adoption of AI for high-stakes R&D. This is capital flowing toward applied AI outcomes, not infrastructure or models.

The key facts

5 to know

  1. $2B deal size

  2. Eli Lilly (major pharma player) committing capital

  3. Hong Kong biotech partner (geographic expansion of AI biotech)

  4. AI drug development focus (vertical application)

  5. Broader trend: pharma aggressively pursuing AI-enabled discovery in China region

Go to the source

Financial Times Technologyft.com

Publisher excerpt: Global pharmaceutical companies are aggressively searching for new medicines in China
Read original report
Back to today's editionMore money news

The wider picture

View all
Paper-cut illustration of amber paths carrying capital toward a small coral research venture between larger buildings.
AI illustration by KeyNews
Money01

Ema raises $77M as AI starts eating into enterprise software and services

Enterprise agent adoption is moving past pilots into production deployments. A capital raise this size signals that agentic systems are becoming a category worth betting on — and that traditional enterprise software vendors face real displacement.

TechCrunch Startups
Paper-cut illustration of amber paths carrying capital toward a small coral research venture between larger buildings.
AI illustration by KeyNews
Money02

Jumbo-Sized Series A Rounds Are On The Rise

Large early-stage funding rounds are surging in 2026, signaling where venture capital is betting on AI infrastructure and autonomy. Practitioners budgeting for competitive positioning and market consolidation need to track which categories are attracting megadeals.

Crunchbase News
Paper-cut illustration of amber paths carrying capital toward a small coral research venture between larger buildings.
AI illustration by KeyNews
Money03

Nvidia-backed Nscale buried ByteDance deal in push to $35bn IPO

A major AI infrastructure company is burying its largest revenue relationship ahead of a public market debut, revealing how U.S.-China tensions are forcing restructuring of the AI compute supply chain and how IPO narratives now actively obscure geopolitical exposure.

Financial Times Technology